Explanation: Triple H therapy is sometimes used after aneurysmal stabilization for patients with symptomatic vasospasm, although not in all settings. The term refers to hypervolemia, hypertension and hemodilution. The effectiveness of this therapy is created by the augmentation of circulating blood flow with increased perfusion pressures. Patients with symptomatic vasospasm require more aggressive volume expansion and hypertension to treat deficits. The goal of triple H therapy is CVP 8-12 mm Hg